OnabotulinumtoxinA for chronic migraine: a critical appraisal

OnabotulinumtoxinA for chronic migraine: a critical appraisal

Rubesh Gooriah, Fayyaz Ahmed Department of Neurology, Hull Royal Infirmary, Kingston Upon Hull, UK Abstract: Chronic migraine (CM) is a severe disabling condition with a few available evidence-based management options. OnabotulinumtoxinA (onaBoNTA) is approved for use in a number of disorders. Its...

Full description

Bibliographic Details
Main Authors:	Gooriah R, Ahmed F
Format:	Article
Language:	English
Published:	Dove Medical Press 2015-06-01
Series:	Therapeutics and Clinical Risk Management
Online Access:	http://www.dovepress.com/onabotulinumtoxina-for-chronic-migraine-anbspcritical-appraisal-peer-reviewed-article-TCRM

Similar Items

Cognitive effects of onabotulinumtoxinA in chronic migraine
by: Susan Ho, et al.
Published: (2020-07-01)

OnabotulinumtoxinA Is an Effective Treatment for Chronic Migraine in Patients With Comorbid Fibromyalgia
by: María Sastre Real, et al.
Published: (2020-10-01)

OnabotulinumtoxinA in the treatment of patients with chronic migraine: clinical evidence and experience
by: Chia-Chun Chiang, et al.
Published: (2017-12-01)

Treatment of Chronic Migraine with OnabotulinumtoxinA: Mode of Action, Efficacy and Safety
by: Délia Szok, et al.
Published: (2015-07-01)

Prediction of patient's response to OnabotulinumtoxinA treatment for migraine
by: Franklin Parrales Bravo, et al.
Published: (2019-02-01)

Adult Abdominal Migraine Improved by OnabotulinumtoxinA Injections
by: Neal Hermanowicz
Published: (2021-09-01)

Critical analysis of the use of onabotulinumtoxinA (botulinum toxin type A) in migraine
by: Robertson CE, et al.
Published: (2012-01-01)

Evidence and experience with onabotulinumtoxinA in chronic migraine: Recommendations for daily clinical practice
by: A.B. Gago-Veiga, et al.
Published: (2019-07-01)

OnabotulinumtoxinA: An Effective Tool in the Therapeutic Arsenal for Chronic Migraine With Medication Overuse
by: Edoardo Caronna, et al.
Published: (2018-10-01)

OnabotulinumtoxinA for chronic migraine during pregnancy: a real world experience on 45 patients
by: Ho-Tin Wong, et al.
Published: (2020-10-01)

OnabotulinumtoxinA in Migraine: A Review of the Literature and Factors Associated with Efficacy
by: Jason C. Ray, et al.
Published: (2021-06-01)

Influence of headache pain intensity and frequency on migraine-related disability in chronic migraine patients treated with OnabotulinumtoxinA
by: Marta Torres-Ferrus, et al.
Published: (2020-07-01)

Economic consequences of migraine in Sweden and implications for the cost-effectiveness of onabotulinumtoxinA (Botox) for chronic migraine in Sweden and Norway
by: Amanda Hansson-Hedblom, et al.
Published: (2020-08-01)

Guideline on the use of onabotulinumtoxinA in chronic migraine: a consensus statement from the European Headache Federation
by: Lars Bendtsen, et al.
Published: (2018-09-01)

Iron Deposits in Periaqueductal Gray Matter Are Associated with Poor Response to OnabotulinumtoxinA in Chronic Migraine
by: Clara Domínguez Vivero, et al.
Published: (2020-07-01)

Long-term study of the efficacy and safety of OnabotulinumtoxinA for the prevention of chronic migraine: COMPEL study
by: Andrew M. Blumenfeld, et al.
Published: (2018-02-01)

Sustained onabotulinumtoxinA therapeutic benefits in patients with chronic migraine over 3 years of treatment
by: Michail Vikelis, et al.
Published: (2018-09-01)

OnabotulinumtoxinA in the treatment of refractory chronic cluster headache
by: Christian Lampl, et al.
Published: (2018-06-01)

Evidence of and experience with the use of onabotulinumtoxinA in trigeminal neuralgia and primary headaches other than chronic migraine
by: S. Santos-Lasaosa, et al.
Published: (2020-10-01)

An open-label prospective study of the real-life use of onabotulinumtoxinA for the treatment of chronic migraine: the REPOSE study
by: Fayyaz Ahmed, et al.
Published: (2019-03-01)

OnabotulinumtoxinA for the treatment of overactive bladder
by: Cox L, et al.
Published: (2014-07-01)

OnabotulinumtoxinA in the treatment of neurogenic bladder
by: Gulamhusein A, et al.
Published: (2012-08-01)

The Impact of OnabotulinumtoxinA vs. Placebo on Efficacy Outcomes in Headache Day Responder and Nonresponder Patients with Chronic Migraine
by: Stephen D. Silberstein, et al.
Published: (2020-10-01)

Real-life use of onabotulinumtoxinA reduces healthcare resource utilization in individuals with chronic migraine: the REPOSE study
by: Katja Kollewe, et al.
Published: (2021-06-01)

High efficacy of onabotulinumtoxinA treatment in patients with comorbid migraine and depression: a meta-analysis
by: Oreste Affatato, et al.
Published: (2021-03-01)

Effects of onabotulinumtoxinA treatment in chronic migraine patients with and without daily headache at baseline: results from the COMPEL Study
by: William B. Young, et al.
Published: (2019-02-01)

Real-world effectiveness of onabotulinumtoxinA treatment for the prevention of headaches in adults with chronic migraine in Australia: a retrospective study
by: Catherine Stark, et al.
Published: (2019-07-01)

Real-life use of onabotulinumtoxinA for symptom relief in patients with chronic migraine: REPOSE study methodology and baseline data
by: Brendan Davies, et al.
Published: (2017-09-01)

Mild systemic inflammation enhances response to OnabotulinumtoxinA in chronic migraineurs
by: Yago Leira, et al.
Published: (2021-01-01)

CALCA and TRPV1 genes polymorphisms are related to a good outcome in female chronic migraine patients treated with OnabotulinumtoxinA
by: R. Moreno-Mayordomo, et al.
Published: (2019-04-01)

Daily Headache in Chronic Migraine Is a Predictive Factor of Response in Patients Who Had Completed Three Sessions of OnabotulinumtoxinA
by: Enrique Martínez-Pías, et al.
Published: (2021-06-01)

Exploring Emotional Distress, Psychological Traits and Attitudes in Patients with Chronic Migraine undergoing OnabotulinumtoxinA Prophylaxis versus Withdrawal Treatment
by: Valeria Donisi, et al.
Published: (2020-09-01)

The Role of OnabotulinumtoxinA in Urology: What Is the Next Step?
by: Hong Sang Moon
Published: (2015-12-01)

Long term outcome for onabotulinumtoxinA (Botox) therapy in chronic migraine: A 2-year prospective follow-up audit of patients attending the Hull (UK) migraine clinic
by: Fayyaz Ahmed, et al.
Published: (2021-01-01)

OnabotulinumtoxinA injections in chronic migraine, targeted to sites of pericranial myofascial pain: an observational, open label, real-life cohort study
by: Danièle Ranoux, et al.
Published: (2017-07-01)

OnabotulinumtoxinA for trigeminal neuralgia: a review of the available data
by: Pedro A. Kowacs, et al.
Published: (2015-01-01)

Improvements in pain, medication use and quality of life in onabotulinumtoxinA-resistant chronic migraine patients following erenumab treatment – real world outcomes
by: J. Talbot, et al.
Published: (2021-01-01)

Novel Applications of OnabotulinumtoxinA in Lower Urinary Tract Dysfunction
by: Jia-Fong Jhang, et al.
Published: (2018-06-01)

Self-Administered Low-Dose Inhaled Methoxyflurane (Penthrox) during Administration of OnabotulinumtoxinA for Chronic Migraines: A Real World Case Series
by: Robert Hauptman
Published: (2019-03-01)

Chronic Migraine and Medication Overuse Headache Worsening After OnabotulinumtoxinA Withdrawn Due to the Severe Acute Respiratory Syndrome-Coronavirus-2 Pandemic
by: Carlo Baraldi, et al.
Published: (2021-04-01)